

REMARKS

Applicants elect Group III (claims 1-5, 9-13, and 17-19) with traverse, and submit that it would not place an unrealistic burden on the Examiner to search Groups I-IV. The claims in Groups I-IV share a common technical feature based on the use of cadherin-11 as an indicator of cell function and modulator of differentiation. Applicants submit that U.S. Patent No. 5,646,250, cited by the Examiner, does not disclose the use of cadherin-11 as an indicator or in modulation of differentiation and neoplastic transformation of cells.

Further, Applicants submit that use of a hormone, monoclonal antibody, and anti-sense nucleotides are species of methods to modulate differentiation or neoplastic transformation of cells.


Applicants submit that the application is now in condition for allowance and respectfully request expedited notification of the same.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

August 29, 2003

By:


Katherine L. Neville
Reg. No. 53,379
Agent for Applicants